I'd like to turn to perhaps another issue, and that is with regard to patents for pharmaceuticals. There has been a lot of discussion in this committee. Generic producers have been here as well as some of the larger pharmaceutical companies, and there seems to be a difference of opinion with regard to IP and pharmaceuticals.
I'd like to hear from both of the witnesses on this.
It's clear the European Union has in place stronger measures to protect intellectual property. These could be advantageous or disadvantageous to the generic companies and to the larger pharmaceutical companies. I'm talking about, for example, the right to appeal, the protection of research, etc.
Even if we were to take the perspective of either of them, we would have to deal with an unequal negotiating stance on the basis of IP protection. What is the impact going to be, from your perspective, on the Canadian economy?